Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Liabilities and Shareholders Equity (2023 - 2025)

Upstream Bio has reported Liabilities and Shareholders Equity over the past 3 years, most recently at $353.8 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $353.8 million for Q4 2025, down 26.56% from a year ago — trailing twelve months through Dec 2025 was $1.6 billion (up 126.99% YoY), and the annual figure for FY2025 was $353.8 million, down 26.56%.
  • Liabilities and Shareholders Equity for Q4 2025 was $353.8 million at Upstream Bio, down from $391.2 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for UPB hit a ceiling of $481.7 million in Q4 2024 and a floor of $117.2 million in Q4 2023.
  • Median Liabilities and Shareholders Equity over the past 3 years was $391.2 million (2025), compared with a mean of $350.5 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 311.03% in 2024 and later fell 26.56% in 2025.
  • Upstream Bio's Liabilities and Shareholders Equity stood at $117.2 million in 2023, then surged by 311.03% to $481.7 million in 2024, then fell by 26.56% to $353.8 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $353.8 million (Q4 2025), $391.2 million (Q3 2025), and $420.5 million (Q2 2025) per Business Quant data.